NASDAQ$VRCA
Verrica Pharmaceuticals Inc · Q4 2023 earnings
Q4 2023 earnings · · Investor relations
Briefing
Reported YCANTH™ revenue of $1.9M, made considerable progress with the launch of YCANTH™ during the first full quarter of commercial operations, and advanced the pipeline.
Verrica Pharmaceuticals reported a net loss of $24.6 million for the fourth quarter of 2023, with product revenue of $1.9 million from YCANTH™ and $0.1 million in collaboration revenues. The company is focused on accelerating the YCANTH™ launch and advancing its pipeline, including a Phase 3 clinical trial for common warts and the completion of enrollment in a Phase 2 study for basal cell carcinoma.
- YCANTH™ revenue reached $1.9 million in Q4 2023.
- Over 200 million lives are now covered on commercial insurance and managed Medicaid plans.
- A permanent J-code for YCANTH™ will be published on April 1, 2024.
- The company completed enrollment in the Phase 2 study evaluating VP-315 for basal cell carcinoma.
Headline financials
Revenue & EPS history
Verrica · Revenue · Quarterly
$1.99M
Forward guidance
Verrica anticipates accelerating the YCANTH™ launch in 2024 and expects initial results from the VP-315 study in the first half of 2024.
Tailwinds
- Growing confidence and adoption in the prescriber base
- Over 200 million commercial and Medicaid lives now covered
- A permanent J-code that will be published on April 1
- A significant decrease in the availability and supply of improperly compounded cantharidin
- Alignment with the FDA on the Phase 3 clinical trial for evaluating YCANTH for the treatment of common warts
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 19 quarterly earnings reports · overlaid with Q4 2023
-2.7%
Avg return
Earnings day
-3.4%
Avg return
5 days after
-0.4%
Avg return
30 days after
42%
13 / 31 earnings
Positive
+18.6%
Q1 2024
Best reaction
-47.9%
Q3 2024
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q1 2026 | -3.8% | -15.3% | — | |
| Q4 2025 | +4.7% | +3.2% | -14.5% | |
| Q3 2025 | +3.2% | +15.8% | +104.7% | |
| Q1 2025 | +2.9% | -0.8% | -3.0% | |
| Q4 2024 | -7.6% | +0.5% | -25.3% | |
| Q3 2024 | -47.9% | -45.8% | -22.2% | |
| Q2 2024 | -44.8% | -43.8% | -62.6% | |
| Q1 2024 | +18.6% | +8.4% | +7.3% | |
| Q4 2023 | -3.0% | -10.1% | +3.5% | |
| Q3 2023 | -13.6% | -17.7% | +7.6% | |
| Q2 2023 | +7.6% | +1.6% | -18.5% | |
| Q1 2023 | -1.4% | -7.1% | -13.9% | |
| Q4 2022 | -6.9% | +1.5% | -21.6% | |
| Q3 2022 | -3.1% | +3.1% | +43.7% | |
| Q2 2022 | +17.1% | +9.6% | +18.8% | |
| Q1 2022 | -1.6% | -7.8% | -63.0% | |
| Q4 2021 | +1.3% | -7.7% | +1.9% | |
| Q3 2021 | -4.2% | -5.9% | -22.2% | |
| Q2 2021 | -1.6% | -0.7% | +12.6% | |
| Q1 2021 | -0.8% | -0.2% | -14.8% | |
| Q4 2020 | -9.6% | -0.2% | +1.3% | |
| Q3 2020 | +13.9% | +13.1% | +32.3% | |
| Q2 2020 | +5.6% | +4.8% | +29.6% | |
| Q1 2020 | +10.5% | +2.8% | +24.0% | |
| Q4 2019 | -12.1% | -7.5% | +31.3% | |
| Q3 2019 | +0.8% | +4.0% | -7.3% | |
| Q2 2019 | +2.6% | -9.3% | -2.3% | |
| Q1 2019 | +1.0% | -3.3% | -23.4% | |
| Q4 2018 | -7.5% | +1.1% | -8.0% | |
| Q3 2018 | -3.8% | +5.6% | -22.7% | |
| Q2 2018 | -0.9% | +2.7% | +13.8% | |
| Q1 2018 | — | — | — | |
| Q4 2017 | — | — | — | |
| Q3 2017 | — | — | — | |
| Q2 2017 | — | — | — | |
| Q1 2017 | — | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro